1-13 of 13
Kathleen Moore
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Abstract CT012: TRX-E-002-1 in treatment-refractory ovarian cancer: Final phase 1 study results from the dose-escalation and dose-expansion cohorts

Jermaine Coward, Ganessan Kichenadasse, Paul Harnett, Kathleen Moore, Minal Barve, James Garner, Mary Lopresti, Don S. Dizon
Journal: Cancer Research
Cancer Res (2021) 81 (13_Supplement): CT012.
DOI: https://doi.org/10.1158/1538-7445.AM2021-CT012
Published: 01 July 2021
View article
Journal Articles

Abstract CT218: Phase 1/2 study of a novel HER2 targeting TLR7/8 immune-stimulating antibody conjugate (ISAC), BDC-1001, alone and in combination with pembrolizumab (pembro) in patients (pts) with HER2-expressing advanced solid tumors

Manish R. Sharma, Richard D. Carvajal, Daniel Catenacci, Leisha A. Emens, Glenn J. Hanna, Dejan Juric, Yoon-Koo Kang, Jeeyun Lee, Keun-Wook Lee, Bob T. Li, Kathleen Moore, Mark D. Pegram, Paula R. Pohlmann, Drew Rasco, Alexander Spira, Arielle L. Heeke, Ding Wang, Lawrence Garbo, Sudhir Manda, Jasgit Sachdev, Shelley E. Ackerman, Heidi LeBlanc, David Dornan, Marcin Kowanetz, Michael N. Alonso, Amreen Husain, Edith A. Perez, Ecaterina Ileana Dumbrava
Journal: Cancer Research
Cancer Res (2021) 81 (13_Supplement): CT218.
DOI: https://doi.org/10.1158/1538-7445.AM2021-CT218
Published: 01 July 2021
View article
Journal Articles

Abstract OT-03-02: Phase 1/2 study of a novel HER2 targeting TLR7/8 immune-stimulating antibody conjugate (ISAC), BDC-1001, as a single agent and in combination with an immune checkpoint inhibitor in patients with advanced HER2-expressing solid tumors

Ecaterina Ileana Dumbrava, Manish R. Sharma, Richard D. Carvajal, Daniel Catenacci, Leisha A. Emens, Shirish M. Gadgeel, Glenn J. Hanna, Dejan Juric, Yoon-Koo Kang, Jeeyun Lee, Keun-Wook Lee, Bob T. Li, Kathleen Moore, Mark D. Pegram, Paula R. Pohlmann, Drew Rasco, Alexander Spira, Antoinette R. Tan, Shelley E. Ackerman, Heidi LeBlanc, David Dornan, Marcin Kowanetz, Michael N. Alonso, Edith A. Perez
Journal: Cancer Research
Cancer Res (2021) 81 (4_Supplement): OT-03-02.
DOI: https://doi.org/10.1158/1538-7445.SABCS20-OT-03-02
Published: 15 February 2021
View article
Journal Articles

Abstract CT124: First-in-human study of SC-004, an antibody-drug conjugate targeting CLDN6/9, in patients with epithelial ovarian cancers

Erika Hamilton, Gini F. Fleming, Premal H. Thaker, Vivek Subbiah, Chris Chen, Abraham Fong, Daniel Brickman, Kathleen Moore
Journal: Cancer Research
Cancer Res (2020) 80 (16_Supplement): CT124.
DOI: https://doi.org/10.1158/1538-7445.AM2020-CT124
Published: 15 August 2020
View article
Journal Articles

Abstract CT166: TRX-E-002-1 in treatment-refractory ovarian cancer - 3-month follow-up results from a phase I study dose escalation phase

Jermaine Coward, Ganessan Kichenadasse, Paul Harnett, Kathleen Moore, Minal Barve, Daniel Berg, James Garner, Don Dizon
Journal: Cancer Research
Cancer Res (2020) 80 (16_Supplement): CT166.
DOI: https://doi.org/10.1158/1538-7445.AM2020-CT166
Published: 15 August 2020
View article
Journal Articles

Abstract CT151: A Phase II study of NLG207 (formerly CRLX101) in combination with weekly paclitaxel in patients with recurrent or persistent epithelial ovarian, fallopian tube or primary peritoneal cancer

Linda Duska, David M. O'Malley, Carolyn Krasner, Russell J. Schilder, Cara Mathews, Kathleen Moore, Premal Thaker, Austin Miller, Christopher Purdy, A.J. Leyco, Christopher Smith, Deborah Mercier, Lucinda Tennant, Eugene Kennedy, Nicholas Vahanian, Charles Link
Journal: Cancer Research
Cancer Res (2019) 79 (13_Supplement): CT151.
DOI: https://doi.org/10.1158/1538-7445.AM2019-CT151
Published: 01 July 2019
View article
Journal Articles

Abstract CT091: Phase I study of intraperitoneal TRX-E-002-1 in patients with persistent or recurrent ovarian cancer, fallopian tube cancer or primary peritoneal cancer: Results of dose-escalation phase

Jermaine Coward, Don Dizon, Ganessan Kichenadasse, Paul Harnett, Kathleen Moore, Minal Barve, Daniel Berg, James Garner
Journal: Cancer Research
Cancer Res (2019) 79 (13_Supplement): CT091.
DOI: https://doi.org/10.1158/1538-7445.AM2019-CT091
Published: 01 July 2019
View article
Journal Articles

Abstract CT012: Open-label, multicenter, Phase Ib study to assess safety, tolerability and efficacy of adavosertib monotherapy in patients with advanced solid tumors: Expansion cohorts

Todd M. Bauer, Kathleen Moore, Janet S. Rader, Fiona Simpkins, Alain Mita, J Thaddeus Beck, Lowell Hart, Quincy Chu, Amit Oza, Anna V. Tinker, Karen So, Esteban Rodrigo Imedio, Sanjeev Kumar, Ganesh M. Mugundu, Suzanne Jenkins, Juliann Chmielecki, Suzanne Jones, David R. Spigel, Siqing Fu
Journal: Cancer Research
Cancer Res (2019) 79 (13_Supplement): CT012.
DOI: https://doi.org/10.1158/1538-7445.AM2019-CT012
Published: 01 July 2019
View article
Journal Articles

Abstract CT036: Targeting MUC16 with the THIOMABTM-drug conjugate DMUC4064A in patients with platinum-resistant ovarian cancer: A phase I expansion study

Kathleen Moore, Erica P. Hamilton, Howard A. Burris, Lisa M. Barroilhet, Martin Gutierrez, Judy S. Wang, Manish R. Patel, Michael J. Birrer, W. Mike Flanagan, Yulei Wang, Amit Garg, Xuyang Lu, Anjali Vaze, Dilip Amin, Douglas Leipold, S. Renee Commerford, Eric W. Humke, Joyce F. Liu
Journal: Cancer Research
Cancer Res (2018) 78 (13_Supplement): CT036.
DOI: https://doi.org/10.1158/1538-7445.AM2018-CT036
Published: 01 July 2018
View article
Journal Articles

Abstract CT092: Pharmacokinetics of a THIOMABTM antibody drug conjugate (TDC): DMUC4064A in a phase 1 study with platinum-resistant ovarian cancer

Amit Garg, Gaohong She, Ian Donatello, Matts Kagedal, Douglas D. Leipold, Ola Saad, Joyce Liu, Kathleen Moore, Erika Hamilton, Howard Burris, Judy Wang, Michael Birrer, Eric Humke, Sandhya Girish
Journal: Cancer Research
Cancer Res (2017) 77 (13_Supplement): CT092.
DOI: https://doi.org/10.1158/1538-7445.AM2017-CT092
Published: 01 July 2017
View article
Journal Articles

Abstract CT153: First in human study of the first-in-class fatty acid synthase (FASN) inhibitor TVB-2640

Gerald Falchook, Manish Patel, Jeffrey Infante, Hendrik-Tobias Arkenau, Emma Dean, Andrew Brenner, Erkut Borazanci, Juanita Lopez, Kathleen Moore, Peter Schmid, Arthur Frankel, Suzanne Jones, William McCulloch, George Kemble, Howard Burris
Journal: Cancer Research
Cancer Res (2017) 77 (13_Supplement): CT153.
DOI: https://doi.org/10.1158/1538-7445.AM2017-CT153
Published: 01 July 2017
View article
Journal Articles

Abstract 414: Prospective profiling of systemic and loco-regional alterations during intraperitoneal chemotherapy for ovarian cancer, results from GOG 271

Shannon Grabosch, Anda M. Vlad, Tianzhou Ma, Jyothi T. Mony, Mary Strange, Joan Brozick, Julia Thaller, George Tseng, Xin Huang, Kathleen Moore, Kunle Odunsi, Robert P. Edwards
Journal: Cancer Research
Cancer Res (2015) 75 (15_Supplement): 414.
DOI: https://doi.org/10.1158/1538-7445.AM2015-414
Published: 01 August 2015
View article
Journal Articles

Abstract LB-290: Targeting MUC16 with the antibody-drug conjugate (ADC) DMUC5754A in patients with platinum-resistant ovarian cancer: A phase I study of safety and pharmacokinetics.

Joyce Liu, Kathleen Moore, Michael Birrer, Suzanne Berlin, Ursula Matulonis, Jeffrey Infante, Jian Xi, Robert Kahn, Yulei Wang, Katie Wood, Daniel Coleman, Daniel Maslyar, Eric Humke, Howard Burris
Journal: Cancer Research
Cancer Res (2013) 73 (8_Supplement): LB-290.
DOI: https://doi.org/10.1158/1538-7445.AM2013-LB-290
Published: 15 April 2013
View article